Literature DB >> 32759993

New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin.

Hamoud Alhebbi1, Abdul Ali Peer-Zada2, Abdulrahman A Al-Hussaini3,4, Sara Algubaisi1, Awad Albassami1, Nasser AlMasri5, Yasir Alrusayni6, Ibrahim M Alruzug7, Essa Alharby8, Manar A Samman2, Syed Zubair Ayoub2, Sateesh Maddirevula9, Roy W A Peake10, Fowzan S Alkuraya4,9, Sami Wali11, Naif A M Almontashiri12,13.   

Abstract

Biallelic variants in the USP53 gene have recently been reported to segregate with normal gamma glutamyltransferase (GGT) cholestasis. Using whole-exome sequencing (WES), we detected two USP53 homozygous variants (c.951delT; p. Phe317fs and c.1744C>T; p. Arg582*) in five additional cases, including an unpublished cousin of a previously described family with intractable itching and normal GGT cholestasis. Three patients, a child and two adults, presented with recurrent episodes of normal GGT cholestasis, consistent with a diagnosis of benign recurrent intrahepatic cholestasis (BRIC). Cholangiopathic changes, possibly autoimmune in origin, were recognized in some patients. Additional phenotypic details in one patient included an enlarged left kidney, and speech/developmental delay. Notably, two patients exhibited a complete response to rifampicin, and one responded to ursodeoxycholic acid (UDCA). Two adult patients were suspected to have autoimmune liver disease and treated with steroids. This report describes new cases of USP53 disease presenting with normal GGT cholestasis or BRIC in three children and two adults. We also describe the novel finding of a dramatic response to rifampicin. The association of cholangiopathy with normal GGT cholestasis provides a diagnostic challenge and remains poorly understood.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32759993     DOI: 10.1038/s10038-020-0811-1

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  48 in total

1.  Cloning and enzymatic analysis of 22 novel human ubiquitin-specific proteases.

Authors:  Víctor Quesada; Araceli Díaz-Perales; Ana Gutiérrez-Fernández; Cecilia Garabaya; Santiago Cal; Carlos López-Otín
Journal:  Biochem Biophys Res Commun       Date:  2004-01-30       Impact factor: 3.575

Review 2.  Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases.

Authors:  Geir Folvik; Olset Hilde; Gilja Odd Helge
Journal:  Scand J Gastroenterol       Date:  2012-01-10       Impact factor: 2.423

3.  TJP2 hepatobiliary disorders: Novel variants and clinical diversity.

Authors:  Jing Zhang; Lang-Li Liu; Jing-Yu Gong; Chen-Zhi Hao; Yi-Ling Qiu; Yi Lu; Jia-Yan Feng; Jia-Qi Li; Zhong-Die Li; Meng-Xuan Wang; Qing-He Xing; A S Knisely; Jian-She Wang
Journal:  Hum Mutat       Date:  2019-11-28       Impact factor: 4.878

4.  Nonsense variant of ATP8B1 gene in heterozygosis and benign recurrent intrahepatic cholestasis: A case report and review of literature.

Authors:  Mariano Piazzolla; Nicola Castellaneta; Antonio Novelli; Emanuele Agolini; Dario Cocciadiferro; Leonardo Resta; Loren Duda; Michele Barone; Enzo Ierardi; Alfredo Di Leo
Journal:  World J Hepatol       Date:  2020-02-27

Review 5.  Benign recurrent intrahepatic cholestasis.

Authors:  Velimir A Luketic; Mitchell L Shiffman
Journal:  Clin Liver Dis       Date:  2004-02       Impact factor: 6.126

6.  Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis.

Authors:  Yi-Ling Qiu; Jing-Yu Gong; Jia-Yan Feng; Ren-Xue Wang; Jun Han; Teng Liu; Yi Lu; Li-Ting Li; Mei-Hong Zhang; Jonathan A Sheps; Neng-Li Wang; Yan-Yan Yan; Jia-Qi Li; Lian Chen; Christoph H Borchers; Bence Sipos; A S Knisely; Victor Ling; Qing-He Xing; Jian-She Wang
Journal:  Hepatology       Date:  2017-03-23       Impact factor: 17.425

7.  Expanding etiology of progressive familial intrahepatic cholestasis.

Authors:  Sarah Af Henkel; Judy H Squires; Mary Ayers; Armando Ganoza; Patrick Mckiernan; James E Squires
Journal:  World J Hepatol       Date:  2019-05-27

8.  Benign Recurrent Intrahepatic Cholestasis Type 2 in Siblings with Novel ABCB11 Mutations.

Authors:  Min Ji Sohn; Min Hyung Woo; Moon-Woo Seong; Sung Sup Park; Gyeong Hoon Kang; Jin Soo Moon; Jae Sung Ko
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2019-02-27

9.  Identification of novel loci for pediatric cholestatic liver disease defined by KIF12, PPM1F, USP53, LSR, and WDR83OS pathogenic variants.

Authors:  Sateesh Maddirevula; Hamoud Alhebbi; Awad Alqahtani; Talal Algoufi; Hessa S Alsaif; Niema Ibrahim; Firdous Abdulwahab; Mohammed Barr; Hamad Alzaidan; Ali Almehaideb; Omai AlSasi; Amal Alhashem; Hussa Al- Hussaini; Sami Wali; Fowzan S Alkuraya
Journal:  Genet Med       Date:  2018-09-25       Impact factor: 8.822

10.  Progressive Hearing Loss in Mice Carrying a Mutation in Usp53.

Authors:  Marcin Kazmierczak; Suzan L Harris; Piotr Kazmierczak; Prahar Shah; Valentin Starovoytov; Kevin K Ohlemiller; Martin Schwander
Journal:  J Neurosci       Date:  2015-11-25       Impact factor: 6.167

View more
  3 in total

1.  Progressive Ataxia and Neurologic Regression in RFXANK-Associated Bare Lymphocyte Syndrome.

Authors:  Essa Alharby; Mona Obaid; Mohammed A O Elamin; Makki Almuntashri; Ismail Bakhsh; Manar Samman; Roy W A Peake; Ali Alasmari; Naif A M Almontashiri
Journal:  Neurol Genet       Date:  2021-04-09

2.  A Two-Year Clinical Description of a Patient with a Rare Type of Low-GGT Cholestasis Caused by a Novel Variant of USP53.

Authors:  Olga Shatokhina; Natalia Semenova; Nina Demina; Elena Dadali; Alexander Polyakov; Oxana Ryzhkova
Journal:  Genes (Basel)       Date:  2021-10-14       Impact factor: 4.096

3.  Computational identification of host genomic biomarkers highlighting their functions, pathways and regulators that influence SARS-CoV-2 infections and drug repurposing.

Authors:  Md Parvez Mosharaf; Md Selim Reza; Md Kaderi Kibria; Fee Faysal Ahmed; Md Hadiul Kabir; Sohel Hasan; Md Nurul Haque Mollah
Journal:  Sci Rep       Date:  2022-03-11       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.